{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:12:52Z","timestamp":1761487972561},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2007,12,1]],"date-time":"2007-12-01T00:00:00Z","timestamp":1196467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2007,12]]},"DOI":"10.1053\/j.seminoncol.2007.11.001","type":"journal-article","created":{"date-parts":[[2008,1,7]],"date-time":"2008-01-07T12:19:03Z","timestamp":1199708343000},"page":"S3-S7","source":"Crossref","is-referenced-by-count":9,"special_numbering":"S5","title":["Clinical Management of T-Cell Malignancies: Current Perspectives, Key Issues, and Emerging Therapies"],"prefix":"10.1053","volume":"34","author":[{"given":"Bruce D.","family":"Cheson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2007.11.001_bib1","first-page":"76","article-title":"Prognostic significance of T-cell phenotype in aggressive non-Hodgkin\u2019s lymphomas","volume":"92","author":"Gisselbrecht","year":"1998","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2007.11.001_bib2","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP plus rituximab compared with CHOP chemotherapy in elderly patients with diffuse large B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2007.11.001_bib3","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1200\/JCO.2005.09.131","article-title":"Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte","volume":"23","author":"Feugier","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2007.11.001_bib4","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"Development of a predictive model for aggressive lymphoma: The International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project","volume":"329","author":"Shipp","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2007.11.001_bib5","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","article-title":"The use of molecular profiling to predict survival after chemotherapy for large B-cell lymphoma","volume":"346","author":"Rosenwald","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2007.11.001_bib6","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1200\/JCO.2005.03.6327","article-title":"Marker expression in peripheral T-cell lymphoma: A proposed clinical-pathologic prognostic score","volume":"24","author":"Went","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2007.11.001_bib7","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1038\/sj.onc.1209178","article-title":"Gene expression profiling identifies molecular subgroups among nodal peripheral T-cell lymphomas","volume":"25","author":"Ballester","year":"2006","journal-title":"Oncogene"},{"key":"10.1053\/j.seminoncol.2007.11.001_bib8","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.1990.8.1.155","article-title":"Phase II trial of intermittent high-dose recombinant interferon alfa-2a in mycosis fungoides and the S\u00e9zary syndrome","volume":"8","author":"Kohn","year":"1990","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2007.11.001_bib9","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1200\/JCO.1994.12.12.2588","article-title":"The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype","volume":"12","author":"Mercieca","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2007.11.001_bib10","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3109\/10428199709109162","article-title":"2-Chlorodeoxyadenosine in cutaneous T-cell lymphoproliferative disorders","volume":"26","author":"Kong","year":"1997","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminoncol.2007.11.001_bib11","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1182\/blood.V87.3.906.bloodjournal873906","article-title":"Phase II trial of 2-chlorodeoxyadenosine for the treatment of cutaneous T-cell lymphoma","volume":"87","author":"Kuzel","year":"1996","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1053\/j.seminoncol.2007.11.001_bib12","first-page":"524a","article-title":"Forodesine IV (Bcx-1777) is clinically active in relapsed\/refractory T-cell leukemia: Results of a phase II study (interim report)","volume":"108","author":"Furman","year":"2006","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1053\/j.seminoncol.2007.11.001_bib13","first-page":"698a","article-title":"Oral forodesine (Bcx-1777) is clinically active in refractory cutaneous T-cell lymphomas: Results of a phase I\/II study","volume":"108","author":"Duvic","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2007.11.001_bib14","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1200\/JCO.1998.16.11.3607","article-title":"Compound GW506U78 in refractory hematologic malignancies: Relationship between cellular pharmacokinetics and clinical response","volume":"16","author":"Gandhi","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2007.11.001_bib15","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1200\/JCO.2005.03.426","article-title":"Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: A report from the Children\u2019s Oncology Group","volume":"23","author":"Berg","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2007.11.001_bib16","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/10428190600961058","article-title":"Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901","volume":"48","author":"Czuczman","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminoncol.2007.11.001_bib17","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1200\/JCO.2000.18.13.2603","article-title":"Gemcitabine treatment in pretreated cutaneous T-cell lymphomas: Experience in 44 patients","volume":"18","author":"Zinzani","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2007.11.001_bib18","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1002\/cncr.21449","article-title":"Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: Phase II study of 32 patients","volume":"104","author":"Marchi","year":"2005","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2007.11.001_bib19","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1023\/A:1008409601731","article-title":"Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients","volume":"9","author":"Zinzani","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2007.11.001_bib20","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1080\/10428190210183","article-title":"Treatment of refractory peripheral T-cell lymphoma with denileukin diftitox (ONTAK)","volume":"43","author":"Talpur","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminoncol.2007.11.001_bib21","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1365-2141.2006.06457.x","article-title":"Phase II trial of denileukin diftitox for relapsed\/refractory T-cell non-Hodgkin\u2019s lymphoma","volume":"36","author":"Dang","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminoncol.2007.11.001_bib22","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2006-06-025999","article-title":"Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)","volume":"109","author":"Duvic","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2007.11.001_bib23","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1182\/blood.V98.9.2865","article-title":"Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: A case report","volume":"98","author":"Piekarz","year":"2001","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2007.11.001_bib24","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1200\/JCO.2005.01.9679","article-title":"Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies","volume":"24","author":"O\u2019Connor","year":"2006","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"10.1053\/j.seminoncol.2007.11.001_bib25","first-page":"122a","article-title":"Pralatrexate (PDX) produces durable complete remissions in patients with chemotherapy resistant precursor and peripheral T-cell lymphomas: Results of the MSKCC phase I\/II experience","volume":"108","author":"O\u2019Connor","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2007.11.001_bib26","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2005.08.100","article-title":"Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin\u2019s lymphoma","volume":"23","author":"Rummel","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2007.11.001_bib27","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1159\/000027163","article-title":"Bendamustine in the treatment of low-grade non-Hodgkin\u2019s lymphomas","volume":"23","author":"Schw\u00e4nen","year":"2000","journal-title":"Onkologie"},{"key":"10.1053\/j.seminoncol.2007.11.001_bib28","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s004320000180","article-title":"Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia","volume":"127","author":"Kath","year":"2001","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1053\/j.seminoncol.2007.11.001_bib29","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1053\/sonc.2002.34877","article-title":"Bendamustine in the treatment of non-Hodgkin\u2019s lymphoma: Results and future perspectives","volume":"29","author":"Rummel","year":"2002","journal-title":"Semin Oncol"},{"issue":"suppl 1","key":"10.1053\/j.seminoncol.2007.11.001_bib30","first-page":"104a","article-title":"Bendamustine and rituximab act synergistically in vitro and are effective in the treatment of relapsed or refractory indolent and mantle cell lymphomas","volume":"102","author":"Rummel","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2007.11.001_bib31","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00432-002-0378-6","article-title":"High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin\u2019s lymphomas","volume":"128","author":"Bremer","year":"2002","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1053\/j.seminoncol.2007.11.001_bib32","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1093\/annonc\/mdf189","article-title":"Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin\u2019s lymphoma","volume":"13","author":"Weidmann","year":"2002","journal-title":"Ann Oncol"},{"issue":"suppl 1","key":"10.1053\/j.seminoncol.2007.11.001_bib33","first-page":"70a","article-title":"Bendamustine HCL (TREANDA) treatment results in high rates of objective response in patients with rituximab-refractory and alkylator-refractory indolent B-cell non-Hodgkin\u2019s lymphoma (NHL): Results from a phase II multicenter single-agent study","volume":"106","author":"Friedberg","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2007.11.001_bib34","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1002\/1097-0142(19830601)51:11<1982::AID-CNCR2820511104>3.0.CO;2-L","article-title":"Treatment of patients with advanced malignant lymphoma using gallium nitrate administration as a seven-day continuous infusion","volume":"51","author":"Warrell","year":"1983","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2007.11.001_bib35","first-page":"1221","article-title":"Phase II evaluation of bolus gallium nitrate in lymphoproliferative disorders: A Southeastern Cancer Study Group trial","volume":"70","author":"Keller","year":"1986","journal-title":"Cancer Treat Rep"},{"key":"10.1053\/j.seminoncol.2007.11.001_bib36","first-page":"823","article-title":"Gallium nitrate in malignant lymphoma: A Southwest Oncology Group study","volume":"67","author":"Weick","year":"1983","journal-title":"Cancer Treat Rep"},{"key":"10.1053\/j.seminoncol.2007.11.001_bib37","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3816\/CLM.2005.n.026","article-title":"Activity of gallium nitrate in refractory T-cell lymphoma","volume":"6","author":"Huang","year":"2005","journal-title":"Clin Lymphoma"},{"key":"10.1053\/j.seminoncol.2007.11.001_bib38","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2007.11.001_bib39","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1200\/JCO.2005.02.050","article-title":"Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin\u2019s lymphoma and mantle cell lymphoma","volume":"23","author":"O\u2019Connor","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2007.11.001_bib40","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2005.03.108","article-title":"A phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin\u2019s lymphoma","volume":"23","author":"Goy","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2007.11.001_bib41","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","article-title":"Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma","volume":"24","author":"Fisher","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2007.11.001_bib42","doi-asserted-by":"crossref","first-page":"440s","DOI":"10.1200\/jco.2006.24.18_suppl.7576","article-title":"A phase II study of bortezomib in relapsed Hodgkin\u2019s lymphoma: Preliminary results of CALGB 50206","volume":"24","author":"Blum","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2007.11.001_bib43","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/00007890-199508000-00010","article-title":"Rapamycin, a potent immunosuppressive drug, causes programmed cell death in B lymphoma cells","volume":"60","author":"Muthukkumar","year":"1995","journal-title":"Transplantation"},{"key":"10.1053\/j.seminoncol.2007.11.001_bib44","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0092-8674(00)00117-3","article-title":"TOR, a central controller of cell growth","volume":"103","author":"Schmelzle","year":"2000","journal-title":"Cell"},{"key":"10.1053\/j.seminoncol.2007.11.001_bib45","first-page":"19","article-title":"Final results of a phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma","volume":"16","author":"Witzig","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2007.11.001_bib46","doi-asserted-by":"crossref","first-page":"430s","DOI":"10.1200\/jco.2006.24.18_suppl.7532","article-title":"Anti-tumor activity of mTOR inhibitor temsirolimus for relapsed mantle cell lymphoma: A phase II trial in the North Central Cancer Treatment Group","volume":"24","author":"Ansell","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2007.11.001_bib47","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.1200\/JCO.2003.09.037","article-title":"Emerging applications of the tumor necrosis factor family of ligands and receptors in cancer therapy","volume":"21","author":"Younes","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2007.11.001_bib48","doi-asserted-by":"crossref","first-page":"711s","DOI":"10.1200\/jco.2005.23.16_suppl.7506","article-title":"Long-term survival results of a randomized multinational phase 3 trial of dacarbazine (DTIC) with or without Bcl-2 antisense (oblimersen sodium) in patients (pts) with advanced malignant melanoma (MM)","volume":"23","author":"Kirkwood","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2007.11.001_bib49","doi-asserted-by":"crossref","first-page":"7697","DOI":"10.1200\/JCO.2005.02.4364","article-title":"Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia","volume":"23","author":"O\u2019Brien","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2007.11.001_bib50","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1200\/JCO.2006.07.1191","article-title":"Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-e antisense) in patients with relapsed or refractory chronic lymphocytic leukemia","volume":"25","author":"O\u2019Brien","year":"2007","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"10.1053\/j.seminoncol.2007.11.001_bib51","first-page":"143a","article-title":"Genasense (Oblimersen sodium, G3139) is active and well-tolerated both alone and with R-CHOP in mantle cell lymphoma","volume":"102","author":"Leonard","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2007.11.001_bib52","doi-asserted-by":"crossref","first-page":"362s","DOI":"10.1200\/jco.2006.24.18_suppl.6605","article-title":"AT-101, a small molecule Bcl-2 antagonist, in treatment naive CLL patients (pts) with high risk features: Preliminary results from an ongoing phase I trial","volume":"24","author":"James","year":"2006","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"10.1053\/j.seminoncol.2007.11.001_bib53","first-page":"135a","article-title":"A phase I trial of the small molecule pan-Bcl-2 family inhibitor GX15-070 administered intravenously (IV) every 3 233ks to patients with previously treated chronic lymphocytic leukemia (CLL)","volume":"106","author":"O\u2019Brien","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2007.11.001_bib54","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.coph.2004.02.006","article-title":"Targeting death receptors in cancer with APO2L\/TRAIL","volume":"4","author":"Kelley","year":"2004","journal-title":"Curr Opinion Pharmacol"},{"key":"10.1053\/j.seminoncol.2007.11.001_bib55","doi-asserted-by":"crossref","first-page":"5343","DOI":"10.1200\/JCO.2005.05.0401","article-title":"Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: Results of a phase II study","volume":"24","author":"Chanan-Khan","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2007.11.001_bib56","doi-asserted-by":"crossref","first-page":"897a","DOI":"10.1182\/blood.V104.11.3284.3284","article-title":"Phase II study of thalidomide in escalating doses for follicular (F-NHL) and small lymphocytic lymphoma (SLL)","volume":"104","author":"Grinblatt","year":"2004","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1053\/j.seminoncol.2007.11.001_bib57","first-page":"703a","article-title":"Early results from a phase II study of lenalidomide monotherapy in relapsed\/refractory indolent non-Hodgkin\u2019s lymphoma","volume":"108","author":"Witzig","year":"2006","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1053\/j.seminoncol.2007.11.001_bib58","first-page":"160a","article-title":"Preliminary results from a phase II study of lenalidomide in relapsed\/refractory aggressive non-Hodgkin\u2019s lymphoma","volume":"108","author":"Wiernik","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2007.11.001_bib59","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1182\/blood-2003-10-3389","article-title":"A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas","volume":"103","author":"Enblad","year":"2004","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1053\/j.seminoncol.2007.11.001_bib60","first-page":"181a","article-title":"Phase I\/II study of a fully human anti-CD30 monoclonal antibody (MDX-060) in Hodgkin\u2019s disease (HD) and anaplastic large cell lymphoma (ALCL)","volume":"102","author":"Ansell","year":"2003","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1053\/j.seminoncol.2007.11.001_bib61","first-page":"647a","article-title":"Safety, antitumor activity and pharmacokinetics of six weekly doses of SGN-30 (anti-CD30 monoclonal antibody) in patients with refractory or recurrent CD30+ hematologic malignancies","volume":"102","author":"Bartlett","year":"2003","journal-title":"Blood"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775407002217?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775407002217?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,30]],"date-time":"2020-04-30T11:39:54Z","timestamp":1588246794000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775407002217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12]]},"references-count":61,"alternative-id":["S0093775407002217"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2007.11.001","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2007,12]]}}}